# OnCo record veliparib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/veliparib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "veliparib" ;
  schema:name "Veliparib"@en ;
  schema:description "Veliparib is a PARP inhibitor that AbbVie tested with chemotherapy in breast cancer. It added nothing to carboplatin before surgery (BrighTNess) and lengthened progression-free but not overall survival with carboplatin and paclitaxel in inherited BRCA advanced disease (BROCADE3), so it was never licensed."@en ;
  schema:url <https://onco.cc/drugs/veliparib/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Veliparib> ;
  schema:citation <https://doi.org/10.1016/S1470-2045(18)30111-6>, <https://doi.org/10.1016/j.annonc.2022.01.009>, <https://doi.org/10.1016/S1470-2045(20)30447-2>, <https://doi.org/10.1016/j.ejca.2024.113580> ;
  onco:status "negative" ;
  onco:modality "Small-molecule PARP inhibitor (weak PARP trapper)" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/>, <https://onco.cc/cancers/tnbc-metastatic/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:targets <https://onco.cc/targets/parp/>, <https://onco.cc/targets/brca/> ;
  onco:companies <https://onco.cc/companies/abbvie/> ;
  onco:trials <https://onco.cc/trials/brightness/>, <https://onco.cc/trials/brocade3/> .